Business
Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)
Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS).
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, July 3, 2018\n\n\n\n\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, July 3, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has concluded its clinical trial held at Rambam Medical Center.  The Oncology Center at Rambam Medical Center is recognized by the European Society for Medical Oncology (ESMO) as a designated Center of Integrated Oncology and Palliative Care.\n\n\n \n\nLaunched in 2016, the study involved patients with advanced Cancer and Cancer Anorexia Cachexia Syndrome (CACS) with Cannabics SR 5mg, daily for 3 months. The main endpoints that were examined were weight gain, appetite and Quality of Life (QOL). The official results are now being evaluated by the Hospital and we expect them to be published in the next few months according to Professor Gil Bar-Sela, who ran the study and is Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients. \n\nThe study is registered with the US NIH under \"Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients\", Identifier NCT02359123, and may be found at https://clinicaltrials.gov/ct2/show/NCT02359123\n\nEyal Ballan, Chief  Technical Officer of Cannabics Pharmaceuticals said: \"We are very pleased to have completed this study. We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on&#...